U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.

Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with most regaining 5% or less of the pounds they shed. A company-funded ...

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...